One patient felt light-headed after one week of treatment and stopped treatment. One patient developed mouth ulcers at 65 weeks and one patient developed a pancytopenia after 51 weeks of treatment. The details of this case are as follows:
A 58-year-old female had suffered from sero-positive rheumatoid disease for 15 years and has been treated with at least ten different 'anti-rheumatic' drugs during that time. She responded well to fenclofenac 1500 mg daily and showed no ill effects until she developed shingles when because of bed rest and subsequent reduction in joint pain she reduced the dose of fenclofenac to 900 mg daily. At this stage, although her hemoglobin was only 9.9 g/dl the white cell count and platelet counts were normal. She increased her fenclofenac to 1500 mg daily and felt better but a month later the white cell count fell to 2200/mm3 and the platelets to 100000/mm3. She was admitted to hospital and a bone marrow specimen was reported as normal. The white blood count and platelets continued to fall for a few days and then on withdrawal of therapy and appropriate antibiotic treatment they gradually rose to normal levels, but subsequent biopsy of a rapidly enlarging gland in the neck proved histologically that the diagnosis was that of an immunoblastic sarcoma which has so far responded well to the appropriate treatment without exacerbation of the rheumatoid disease.
Six patients had gastrointestinal side-effects severe enough to withdraw therapy. Diarrhoea occurred in 3 patients and hematemesis in one. He was a 57-year-old male with a 30-year history of rheumatoid disease. Two years previously he had been admitted to hospital with abdominal pain and vomiting. Clinically the diagnosis was a peptic ulcer but the barium meal was normal. After seven days of fenclofenac therapy his hemoglobin began to fall and after 25 days he had a severe melkna which necessitated blood transfusion. In retrospect, because of his past history, he should not have been given this drug.
Two patients developed abdominal pain and vomiting at three days and three weeks respectively.
Gastrointestinal Intolerance
Sixteen patients gave a history of previous gastrointestinal intolerance (i.e. severe enough to withdraw therapy) to at least one drug, mostly two drugs, but only 5 of these patients showed intolerance to fenclofenac.
Twenty-two patients gave no history of gastrointestinal intolerance to up to five different agents (average 2) and only one stopped fenclofenac with diarrheea. The tolerability of any new drug is one of the main features that will decide its acceptability by both patient and doctor. The side-effects in 38 patients suffering from rheumatoid arthritis and treated with fenclofenac for up to two years were looked at in detail with special reference to the gastrointestinal tract. All of the patients admitted to the study had demonstrated a less than optimal response to previous therapy. In addition 16 patients gave a history of gastrointestinal intolerance to previous therapy, 7 patients had a history of allergy, 6 were known to have developed either rash or albuminuria on gold therapy and several patients had presented with a history of both gastrointestinal symptoms and allergy. The dose of fenclofenac used throughout this study was 900-1800 mg daily in divided doses.
Fourteen patients are still on therapy and their disease has been satisfactorily controlled for an average of 54 weeks (range 19-116 weeks) without side-effects.
Twenty-four patients have stopped treatment with fenclofenac. In 8 patients their disease was not adequately controlled by the drug.
One patient tolerated fenclofenac long enough to go into remission and one patient developed a chest infection with subsequent collapse of the right middle lobe and it was thought advisable to stop fenclofenac. This patient subsequently responded to antibiotic therapy, the middle lobe re-expanded and a full recovery was made.
Fourteen patients had therapy stopped because of side-effects. Skin rashes occurred in 5 patients; all except one arose in the first four weeks of treatment and rapidly cleared when therapy was stopped. One patient developed a generalized rash after 75 weeks of fenclofenac therapy; the rash did not improve when the therapy was withdrawn and a subsequent dermatological opinion indicated that this rash was not drug induced. However, as the patient's rheumatoid disease did not flare up when fenclofenac was stopped it was not reintroduced.
Eight patients escaped the trial criteria of exclusion because of gastrointestinal disease and were later found to have had gastrointestinal disease-they were patients with a past history of melena, hiatus hernia, gall-stones, gastrectomy, possible duodenal ulcer, acute gastric erosion, duodenal ulcer and haematemesis, and vagotomy and pyloroplasty. Four of these patients stopped fenclofenac therapy within four weeks, two of whom had gastrointestinal troubles. The patient with a hiatus hernia developed abdominal pain as did the patient with gall-stones. The other 2 stopped for other reasons not related to the gastrointestinal tract. The other 4 patients tolerated the drug for more than four weeks (average 37 weeks) without gastrointestinal trouble.
Temporary gastrointestinal upsets such as heartburn, vomiting, &c., were reported by 7 patients but none stopped therapy for more than one to two days and all tolerated subsequent higher doses without incident, except 2 who continued to tolerate 1200 mg daily without trouble but nausea or vomiting was experienced with higher doses.
The tolerance of any drug when mixed with supportive therapy is important and of this group 18 patients were taking additional non-rheumatic treatment in the form of hypotensive agents, diuretics, iron, &c., and only 4 of this group had therapy stopped because of any side-effects and only one of these related to the gastrointestinal tracta patient on iron developing abdominal pain.
Summary
Fenclofenac is tolerated by the gastrointestinal tract as well as any other non-steroidal antiinflammatory agent. The majority of side-effects occur in the first four weeks of therapy and fenclofenac can be mixed with other drugs without any increased incidence of side-effects. Fenclofenac should not be given to patients with active gastrointestinal disease, but a history of intolerance of the other non-steroidal anti-inflammatory drugs does not preclude the use of fenclofenac in these patients.
DISCUSSION
Dr Bacon asked Dr Smith about the incidence of rashes in the therapeutic dose range. Dr Smith said it was the same throughout the dose range studied and had occurred in 6-7 % of patients treated in the open study. Dr Ansell said that fenclofenac was obviously going to be useful because of its lack of gastrointestinal problems. The possibility that it might well have a long-term effect had been alluded to and must now be investigated.
